Alzheimer disease (AD) is the most common neurodegenerative disorder and lacks effective disease-modifying therapies. In 2001, we initiated a clinical trial of nerve growth factor (NGF) gene therapy in AD, the first effort at gene delivery in an adult neurodegenerative disorder. This program aimed to determine whether a nervous system growth factor prevents or reduces cholinergic neuronal degeneration in patients with AD. We present postmortem findings in 10 patients with survival times ranging from 1 to 10 years after treatment.

Mark H. Tuszynski, MD, PhD, of the University of California, San Diego, and colleagues hoped to determine whether degenerating neurons in AD retain an ability to respond to a nervous system growth factor delivered after disease onset.

READ FULL ARTICLE Curated publisher From archneur.jamanetwork.com